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A B S T R A C T
Objectives: We examined HIV sero-positivity and risk factors in patients admitted with ischaemic stroke (IS) and
haemorrhagic stroke (HS) in Kampala, Uganda.
Study design: We conducted a matched case-control study between December 2016 and December 2018 at St
Francis Hospital, Nsambya.
Methods: The study population comprised of stroke cases (adults aged 18 years with IS or HS confirmed by
neuroimaging) and controls (age- and sex-matched stroke-free adults aged 18 years who were recruited from the
same hospital as the cases). A comprehensive assessment for sociodemographic, lifestyle and clinical factors was
performed using the World Health Organization (WHO) STEP-wise approach to Surveillance (STEPS) for stroke
risk factor surveillance. We used conditional logistic regression to identify risk factors associated with IS or HS.
Results: We enrolled 137 matched case-control pairs; 48 (35%) were men, and the mean ages were 62.4 years (SD
 14.8) for cases and 61.1 years (SD  14.1) for controls. Of stroke patients, 86 (63%) had IS and 51 (37%) had
HS. Overall, HIV sero-positivity was 10% among stroke cases versus 7% among controls. HIV sero-positivity was
not significantly associated with stroke (unadjusted odds ratio [uOR] ¼ 1.49, 95% confidence interval [CI]
0.59–3.78). A self-reported family history of diabetes mellitus was associated with an increased risk of all stroke
(adjusted odds ratio [aOR] ¼ 4.41, 95% CI 1.47–13.2), as well as for IS and HS separately (aOR ¼ 3.66, 95% CI
1.09–12.4 and aOR ¼ 4.99, 95% CI 1.02–24.4, respectively). High blood pressure (140/90 mmHg) was asso-
ciated with an increased risk of all stroke (aOR ¼ 12.3, 95% CI 42–44.1), and this was also true for IS and HS
individually (aOR ¼ 6.48, 95% CI 1.15–36.7 and aOR ¼ 5.63, 95% CI 1.74–18.2, respectively).
Conclusions: No association was found between HIV sero-positivity and stroke occurrence among Ugandan stroke
patients. Hypertension and a self-reported family history of diabetes mellitus were significant risk factors for both
IS and HS. Interventions to reduce hypertension and diabetes mellitus in the Ugandan population are urgently
required. Much larger studies are required to demonstrate if any association exists between HIV and stroke.
1. Introduction
Stroke remains one of the leading causes of morbidity and mortality
worldwide [1]. Over 80% of stroke deaths occur in low- and
middle-income countries (LMICs), including in sub-Saharan Africa (SSA)
[2]. In Uganda, stroke accounts for 3.7% of all hospital admissions and is
one of the top five causes of death in adults [1]. However, the relative
contribution of haemorrhagic stroke (HS) and ischaemic stroke (IS) to the
overall burden appears to vary considerably between populations,
countries and regions [3]. The INTERSTROKE study, conducted in 22
countries, found that HS was highest in African countries at 34%,
compared with high-income countries, where HS was 9% [3]. However,
other studies conducted in SSA countries, such as Uganda and Zambia,
have reported higher IS proportions of 69.3% and 65%, respectively,
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than HS [4,5].
HIV is a major public health concern worldwide [6]. SSA countries
have the highest incidence, with nearly 70% of the global burden of
HIV/AIDS [7]. In Uganda, HIV prevalence increased from 6.4% in
2004/05 to 7.3% in 2011, then decreased to 6.2% in 2016 [8–10]. HIV
infection is an emerging vascular risk factor for stroke occurrence and it
is now well recognised that it could potentially increase an individual’s
risk for stroke [11,12]. Between 1% and 5% of patients with HIV develop
stroke, although a higher proportion (4–34%) have cerebral ischaemic
lesions [13]. Potential causes of stroke in individuals with HIV include
opportunistic infections, tumours, coagulopathies and direct HIV infec-
tion of the arterial wall [14].
Several epidemiological studies have identified risk factors for stroke
in SSA [12,15]. More recently, HIV has been noted as a novel risk factor
for stroke, with an increased risk of 5.61 (95% confidence interval [CI]
2.41–13.09; p < 0⋅0001) compared with the general population [12].
Other previous studies in Malawi and South Africa have also suggested
that HIV positivity is a significant independent risk factor for stroke [11,
16]. However, some authors have suggested that the occurrence of stroke
and HIV infection might often be coincidental [14].
The INTERSTROKE study demonstrated the frequency of the main
risk factors for stroke worldwide, including SSA [3]. These are classified
into non-modifiable factors, including older age, male gender and family
history, and modifiable risk factors, including hypertension, diabetes
mellitus (DM), obesity, dyslipidaemias, physical inactivity, low vegetable
and fruit diet, heavy alcohol consumption and cigarette smoking [3,15].
The most common modifiable risk factor for stroke in SSA, including
Uganda, remains hypertension [15]. Unfortunately, in SSA more than
70% of people are unaware of their hypertensive condition, and less than
3% have adequately controlled blood pressure (BP) [17]. In a community
survey conducted in Uganda, the prevalence of uncontrolled hyperten-
sion was 20.2% [17]. In another rural Ugandan study, untreated hyper-
tension, adjusted for age, ranged from 24.9% to 33% [18].
Previous research has shown that stroke subtypes have varying aeti-
ologies, varying prognoses, and require different treatment and preven-
tion strategies [19,20]. For example, in Zambia, HIV infection was
independently associated with IS [4]. In the INTERSTROKE study, DM
was not associated with stroke among Africans overall, but it was asso-
ciated with both stroke types (with a higher effect size in IS than HS) in
Nigeria and Ghana [3,15]. A systematic review found that hypertension
was a key risk factor for stroke, but there were no statistically significant
differences by stroke type [21]. Establishing the distinctive risk factors
for each type of stroke has important implications for its management as
well as primary and secondary prevention [22].
However, there remain insufficient data in SSA to reliably estimate
the effect of various factors on the risk for IS and HS separately. In a
recent systematic review [21], only five case-control studies were iden-
tified from SSA that reported information on risk factors for all stroke,
and only one study reported data on IS and HS risk factors separately.
Identification of locally preventable risk factors associated with different
types of strokes remains an urgent issue and will help inform the Ugan-
dan non-communicable disease (NCD) control programme to prioritise
prevention/control strategies. In this hospital-based case-control study,
we examine HIV sero-positivity and risk factors in patients admitted with
IS and HS in Kampala, Uganda.
2. Methods
2.1. Study design and setting
We conducted a matched case-control study between December 2016
and December 2018 at Nsambya hospital, which is a large urban, private-
not-for-profit hospital in Kampala, the capital city of Uganda. The hos-
pital is situated approximately 5 km (3.1 miles) southeast of the central
business district of Kampala. It is a tertiary referral hospital, receiving
patients from all parts of the country. Most of the patients pay personal
private fees for treatment, while others have insurance cover. Nsambya
Hospital has an average of 19,000 admissions per year and treats an
average of 300 out-patients per day.
2.2. Participants
A ‘case’ was defined as a patient who presented at Nsambya hospital
within 7 days of the onset of symptoms during the study period. For in-
clusion, the patient had to meet the World Health Organization (WHO)
stroke definition of rapidly developing clinical signs of focal or global
disturbance of cerebral function, lasting for more than 24 h or until
death, with no apparent non-vascular cause [23] and with neuroimaging
to confirm the stroke results.
A ‘control’ was defined as a patient attending the study hospital
(where cases were recruited), who was in the same age range age (5
years) as the stroke patient, but without any history or current clinical
diagnosis of stroke.
The eligibility criteria for participation in the study as a case patient
included [1]: being an adult aged 18 years old [2]; presenting within 7
days of the onset of symptoms; and [3] meeting the WHO stroke defi-
nition [23]. We excluded participants who were [1]: unable to consent or
for whom consent could not be obtained from a caregiver [2]; unable to
communicate and without a caregiver respondent; and [3] those who
died within 24 h on the ward before neuroimaging was performed.
2.3. Selection and recruitment of cases
All consenting and confirmed cases of IS and HS by neuroimaging
(computed tomography [CT] scan or magnetic resonance imaging [MRI])
were selected and recruited prospectively into the study. All cases were
recruited consecutively until the required sample size was achieved. We
used the standard WHO definition of stroke [23] and included both
first-ever and recurrent stroke patients. To maximise recruitment and
reduce selection bias, extensive awareness campaigns about the study
were conducted within the hospital departments by the study team. Any
possible cases of incident stroke patients in the outpatient department or
emergency or medical wards were notified to the study team as soon as
possible for assessment. Individuals with a clinical diagnosis of stroke
were further evaluated by the study physicians and investigations per-
formed. This prompt notification was particularly important to ensure
that patients who were recovering from stroke were not missed for
enrolment.
2.4. Selection and recruitment of controls
We recruited hospital-based controls, focusing on patients with con-
ditions that were not related to stroke, other cardiovascular diseases or
cancer (which may share some risk factors, such as smoking or HIV
infection). Controls were approached at random (i.e. whoever seemed to
be within the age/sex group of the cases), and one control patient was
selected per case patient. If a control patient could not consent, another
person was approached until sufficient controls were recruited. All par-
ticipants were given an identification number to ensure that study pro-
cedures were performed anonymously. Control patients were recruited
during the same study period as the case patients. Controls were matched
by age (5 years) and sex to minimise the potential confounding effect.
2.5. Study procedures
A modified questionnaire for the WHO STEP-wise approach to
chronic disease risk factor surveillance (STEPS) and WHO STEP- wise
approach to stroke surveillance [24] were used for data collection. The
variables included non-modifiable risk factors (i.e. age, sex, socioeco-
nomic status, and family history of stroke, hypertension and diabetes),
modifiable risk factors (i.e. hypertension, DM, physical activity level, diet
and alcohol use, smoking status, blood pressure) and other risk factors,
G. Namale et al. Public Health in Practice 2 (2021) 100128
2
such as HIV infection, which were recorded for both cases and controls.
A medical examination was performed to determine systolic and
diastolic arterial BP. BP measurements were taken on the left arm with
the participant in the sitting position. Three sequential readings were
taken, 3–5 min apart, and an average value was taken. A mean BP of
140/90 mm Hg was classified as hypertension. For case patients, the
distinction between stroke subtypes (i.e. IS and HS) was based on CT scan
or MRI findings. Neuroimaging was performed within 48 h of hospital
admission. The images were reported by a radiologist and subsequently
reviewed by a physician.
HIV diagnosis was determined by two rapid tests in parallel (Unigold
and Determine; Bioline, was used as a tiebreaker in situations of
discrepant results, as per national guidelines [25]). Data on the
confirmed HIV test result was recorded in the patient’s file; if this was not
available, the research team attempted to locate the information from
laboratory records.
The bodyweight of many cases patients could not be determined with
the equipment available due to their post-stroke disability and being bed
ridden; thus, body mass index (BMI) was assessed using self-reported
standardised pictorial images of women and men with known BMI
values [26].
The modified-Rankin scale (mRS) [27] was used to measure the
pre-stroke functional ability.
2.6. Definition of study measures
Participants were classified as hypertensive if their BP (mean of three
measurements) was 140/90 mmHg or if there was a self-reported his-
tory of hypertension or history of receiving anti-hypertensive medica-
tions. DM was defined as a history of diabetes, use of drugs to control
diabetes or a fasting blood glucose concentration >7.0 mmol/L,
measured at first encounter. Smoking status was defined as never, former
or current smoker. We defined current smokers as individuals who
smoked any tobacco in the previous month and included those who had
stopped within the preceding month. Former smokers were defined as
those who had stopped >1 month earlier. Dietary history included reg-
ular intake of food items such as fruits and vegetables. Regular intake was
defined as consuming five or more servings weekly. Alcohol use was
assessed using a standardised WHO Alcohol Use Disorders Identification
Test (AUDIT) [28]. Alcohol use was classified into three categories (i.e.
harmless or low-risk drinkers: score 1–7; harmful or high-risk drinkers:
score 8–19; and alcohol-dependent: score 20). A family history of
stroke, hypertension and DM was defined as an immediate family
member (parent, sibling or child) having a similar disease. Obesity was
defined as a BMI of 30 kg/m2. Pre-stroke functional status was assessed
using the mRS: (i) mRS 0–2 was considered good; (ii) mRS 3 was fair; and
(iii) mRS 4–5 indicated a poor outcome.
2.7. Sample size estimation
A sample size of 282 participants was required to assess the risk
factors for both HS and IS stroke subtypes. Approximately 96 cases (and
96 controls) were needed for HS and 32 cases (and 32 controls) for IS.
The sample was adjusted for a 10% rate of non-response. Sample esti-
mates were based on the INTERSTROKE study [3], which assumes a
proportion of hypertension in the controls with no history of stroke of
37% and a lower limit odds ratio (OR) for hypertension of 6.8 comparing
cases of HS and 2.7 comparing cases of IS to controls. Correlation co-
efficients for exposure between matched cases and controls were esti-
mated as 0.29 for HS and 0.36 for IS from the INTERSTROKE study. An
80% power and a two-sided level of significance of 0.05 was assumed.
2.8. Data analysis and quality assessment
Data were double entered in OpenClinica, cleaned and exported to
STATA 15.0 (StataCorp, College Station, TX, USA) for analysis. We
resolved discrepancies by checking the source documents for clarifica-
tion for all possible confounders. Sociodemographic and clinical char-
acteristics of the study participants were compared between cases and
controls using the McNemar test for paired categorical outcomes. Using
conditional logistic regression models, a crude analysis was conducted to
determine the predictors of stroke by comparing cases to controls for
each of the potential risk factors. Factors for which the association
attained statistical significance on log-likelihood ratio test (LRT) [p <
0.20] were selected for the multivariable analysis. All the covariates that
showed a strong relationship with outcome were also considered for
multivariable analysis. We estimated the adjusted odds ratios (aORs) and
95% confidence intervals (CIs) in the final models using conditional lo-
gistic regression modelling. We used the STrengthening the Reporting of
OBservational studies in Epidemiology (STROBE) case-control reporting
guidelines for methodological quality assessment [29].
2.9. Availability of data
The data collected in this study is suitable for sharing and procedures
for accessing it are contained in the data sharing policy accessible from




During the study period, 151 patients were screened; of these, 10
(7%) were excluded from analysis due to ineligibility (including, those
who died within 24 h on the ward before CT scan was performed [n¼ 4];
those who had transient ischemic attacks [n ¼ 4]; and those who pre-
sented 7 days after onset of symptoms [n¼2]). In terms of control pa-
tients, 148 were screened and, of these, 7 (5%) were excluded (because
they could not consent and their caregiver was not available at time of
interview [n ¼ 3] or because of a previous history of stroke [n ¼ 4]).
Thus, in total, 137 matched case-control pairs were enrolled and 4 un-
matched pairs. The unmatched pairs (n¼ 4) were excluded from the final
analysis (see Fig. 1).
3.2. Participant demographic and clinical characteristics
We analysed 137 matched case-control pairs; 48 (35%) were male
stroke patients, with mean ages of 62.4 years (SD  14.8) for cases and
61.1 years (SD  14.1) for controls. Of the case patients, 86 (63%) had IS
and 51 (37%) had HS. The mean age of HS patients (61.5  14.3 years)
was significantly younger than IS patients (62.8  15.0 years) [see
Fig. 2]. More than half (n ¼ 77; 51%) of all stroke cases were aged 60
years. The median time between the onset of symptoms and medical
attention for IS patients was 2 days (interquartile range [IQR]: 1–4 days)
compared with 1 day for HS patients (IQR: 1–5 days); this was not sta-
tistically significant (p ¼ 0.936). Compared with controls, case patients
had a significantly higher proportion of family members with DM (57.9%
vs 42.1%) and recorded higher BPs (140/90 mmHg; 70.2% vs 29.8%).
Other participant characteristics did not differ between control and case
patients. Regarding the functional status, the pre-stroke mRS for all
stroke patients before enrolment were 129 (94.1%) for mRS 0–2, 5
(3.7%) for mRS 3 and 3 (2.2%) for mRS 4–5 (see Table 1).
3.3. HIV sero-positivity
The overall proportion of HIV sero-positivity was 13 of 128 (10%) for
stroke cases versus 9 of 128 (7.0%) for stroke-free controls (p ¼ 0.702).
The mean age of HIV sero-positive patients with stroke was 55 years (SD
 12.9) versus years 57 years (SD  13.0) for control patients (p ¼
0.722). However, with regard to antiretroviral therapy (ART) initiation,
there were no significant differences between HIV sero-positive stroke
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cases and stroke-free controls. The proportion of HIV sero-positivity
among HS patients was 5 of 47 (10.6%) compared with 8 of 84 (9.5%)
among IS patients, which was also not statistically different (p ¼ 0.801)
(Table 1).
3.4. Risk factor association with all stroke and stroke type
Table 2 shows the results of univariate and multivariate analyses. In
the univariate analysis, a family history of DM (uOR ¼ 2.50, 95% CI
1.45–4.32) and a BP  140/90 (uOR ¼ 4.82, 95% CI 2.52–9.22) were
associated with all stroke. HIV sero-positivity and excessive alcohol use
were not significantly associated with stroke (uOR ¼ 1.49, 95% CI
0.59–3.78 and uOR ¼ 1.07, 95% CI 0.64–1.77, respectively) (see
Table 2).
In the adjusted (multivariable) analysis, a self-reported family history
of DM was associated with an increased risk of all stroke (aOR ¼ 4.41,
95% CI 1.47–13.2), as well as for IS and HS separately (aOR ¼ 3.66, 95%
CI 1.09–12.4 and aOR ¼ 4.99, 95% CI 1.02–24.4, respectively). High BP
(140/90 mmHg) was associated with an increased risk for all stroke
(aOR ¼ 12.3, 95% CI 3.42–44.1.0), and this was also true for IS and HS
individually (aOR ¼ 6.48, 95% CI 1.15–36.7 and aOR ¼ 5.63, 95% CI
1.74–18.2, respectively) (Table 2).
Fig. 1. Recruitment profile for stroke cases and controls at Nsambya hospital in Kampala, Uganda (2016–2018).
Fig. 2. Dot plot showing age for ischaemic and haemorrhagic stroke patients in Kampala, Uganda (2016–2018).
G. Namale et al. Public Health in Practice 2 (2021) 100128
4
Table 1
Participant characteristics by case-control status and stroke type in Kampala, Uganda (2016–2018).















Age (years) [mean (SD)] 62.4 (14.8) 61.1 (14.1) 0.494 62.8 (15.0) 61.4 (15.2) 61.5 (14.3) 60.6 (14.3)
Age (years) (n¼274) 0.808
- < 60 60 (49) 62 (51) 36 (47) 40 (53) 24 (52) 22 (48)
-  60 77 (51) 75 (49) 50 (52) 46 (48) 27 (48) 29 (52)
Gender, male (n¼274) 48 (50) 48 (50) – 31 (50) 31 (50) 17 (50) 17 (50)
Education level (n¼274) 0.275
-No education 18 (60) 12 (40) 12 (71) 5 [29] 6 (46) 7 (54)
-Primary 56 (53) 50 (47) 34 (52) 32 (48) 22 (55) 18 [45]
-Secondary & above 63 (46) 75 (54) 40 [45] 49 (55) 23 (47) 26 (53)
Self-reported history of HTN (n¼260) 0.106
- Yes 76 (55) 63 (45) 48 (57.8) 35 (42.2) 28 (50) 28 (50)
- No 54 [45] 67 (55) 33 (41.8) 46 (58.2) 21 (50) 21 (50)
Self-reported history of DM (n¼268) 0.757
- Yes 25 (48) 27 (52) 19 (59.4) 13 (40.6) 6 [30] 14 (70)
- No 109 (50) 107 (50) 65 (47.8) 71 (52.2) 44 (55) 36 [45]
Family history of stroke (n¼264)
- Yes 39 (44.8) 48 (55.2) 0.402 28 (48.2) 30 (51.7) 11 (37.9) 18 (62.1)
- No 80 (51.6) 75 (48.4) 47 (49) 49 (51) 33 (55.9) 26 (44.1)
- Don’t know 13 (59.1) 9 (40.9) 9 (64.3) 5 (35.7) 4 (50) 4 (50)
Family history of DM (n¼266) <0.001
- Yes 99 (57.9) 72 (42.1) 64 (58.7) 45 (41.3) 35 (56.5) 27 (43.5)
- No 34 (35.8) 61 (64.2) 21 (34.4) 40 (65.6) 13 (38.2) 21 (61.7)
Family history of HTN (n¼268) 0.440
- Yes 89 (47.6) 98 (52.4) 54 (45.4) 65 (54.6) 35 (51.5) 33 (48.5)
- No 33 (54.1) 28 (45.9) 23 (60.5) 15 (39.5) 10 (43.5) 13 (56.5)
- Don’t know 12 (60) 8 (40) 8 (61.5) 5 (38.5) 4 (57.1) 3 (42.8)
Current smoking (n¼268)
- Yes 27 (61.4) 17 (38.6) 0.099 17 (68.0) 8 (32.0) 10 (52.6) 9 (47.4)
- No 107 (47.8) 117 (52.2) 68 (46.9) 77 (53.1) 39 (49.4) 40 (50.6)
Alcohol use (n¼274) 0.782
-Low risk drinkers 101 (49.5) 103 (50.4) 69 (51.1) 66 (48.9) 32 (46.4) 37 (53.6)
-Harmful/high risk 36 (51.4) 34 (48.6) 17 (45.9) 20 (54.1) 19 (57.6) 14 (42.4)
Blood pressure  140/90 (n¼260) <0.001
- Yes 73 (70.2) 31 (29.8) 41 (69.5) 18 (30.5) 32 (71.1) 13 (28.8)
- No 57 (36.5) 99 (63.5) 39 (38.6) 62 (61.4) 18 (32.7) 37 (67.3)
Taking anti-HTN drugs (n ¼ 272) 0.145
- Yes 71 (54.6) 59 (45.4) 46 (58.2) 33 (41.7) 25 (49.0) 26 (51)
- No 65 (45.8) 77 (54.2) 39 (42.9) 52 (57.1) 26 (51) 25 (49)
Taking anti-DM drugs (n¼254) 0.200
- Yes 20 (41.8) 28 (58.3) 17 (56.7) 13 (43.3) 3 [7] 15 (83)
- No 107 (51.9) 99 (48.1) 64 (48.5) 71 (51.5) 43 (58.1) 31 (41.9)
Taking aspirin (n¼266) 0.161
- Yes 23 (60.5) 15 (39.5) 13 (54.2) 11 (45.8) 12 (14.2) 2 [4]
- No 110 (48.2) 118 (51.8) 69 (49.3) 71 (50.7) 49 (55.7) 39 (44.3)
Regular fruit diet (n¼246) 0.089
- 0–4 days 8 (50.9) 78 (49.1) 52 (51.5) 49 (48.5) 29 (50) 29 (50)
- 5–7 days 27 (41.5) 38 (58.5) 16 (42.1) 22 (57.9) 11 (40.7) 16 (59.3)
- Don’t know 15 (68.2) 7 (31.8) 8 (61.5) 5 (38.5) 7 (77.8) 2 (22.2)
Regular vegetable diet (n¼240) 0.690
- 0-4 73 (50.3) 72 (49.7) 45 (50.0) 45 (50.0) 28 (50.9) 27 (49.1)
- 5-7 37 (47.4) 41 (52.6) 25 (51.0) 24 (49.0) 12 (41.4) 17 (58.6)
- Don’t know 10 (58.8) 7 (41.2) 4 (44.4) 5 (55.6) 6 (75.0) 2 (25.0)
Obese (n¼274) 0.468
- Yes 28 (45.9) 33 (54.1) 20 (51.2) 10 (48.7) 8 (36.4) 14 (63.6)
- No 109 (51.2) 104 (48.8) 66 (49.6) 67 (50.3) 43 (53.8) 37 (46.2)
HIV status (n¼256) 0.702
- Positive 13 (59.1) 9 (40.9) 8 (61.5) 5 (38.4) 5 (55.6) 4 (44.4)
- Negative 68 (49.3) 70 (50.7) 44 (48.4) 7 (51.6) 24 (51.1) 23 (48.9)
- Don’t know 47 (49.0) 49 (51.0) 29 (50.0) 29 (50.0) 18 (47.4) 20 (52.6)
On ART treatment (n ¼ 222) 0.722
- Yes 6 (50) 6 (50) 4 (50.0) 4 (50.0) 2 (50) 2 (50)
- No 105 (50) 105 (50) 66 (50.0) 66 (50.0) 39 (50) 39 (50)
Pre-stroke functional status (n¼137)b
-mRS 0–2 129 (94.1) 63 (90) 48 (100)
-mRS 3 5 (3.7) 4 [6] 0 (0)
–mRS 4–5 3 (2.2) 3 [4] 0 (0)
Median time between onset of symptoms and
medical attention [days (IQR)] (n¼137)ƚ
2 [1–4] 2 [1–4] 1 [1–5]
ART; antiretroviral therapy; DM, diabetes mellitus; HTN, hypertension.
a P-values are Chi-square for categorical and T-test for continuous variables.
b Question applied only to case patients.
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4. Discussion
4.1. Summary of the main findings
In this case-control study, risk factors have been identified, including
a family history of diabetes and high BP (140/90 mmHg), that are
associated with both HS and IS among individuals in Uganda. Overall,
the patients presenting with stroke in this study had a much higher
prevalence of vascular risk factors, particularly hypertension and dia-
betes, than the general population in Uganda. Our study provides
essential information on the importance of the most common, potentially
preventable, risk factors and builds on previous epidemiological studies
from SSA and other parts of the world [3,15]. These findings are
important in guiding the selection of interventions used to target modi-
fiable risk factors for the prevention of cardiovascular disease, including
stroke, in Uganda.
4.2. Interpretations
Similar to other findings in SSA [30], in this study, we did not find any
association between HIV sero-positivity and stroke occurrence. In
contrast, a study in Malawi found that HIV infection was significantly
associated with stroke [11]. In fact, other reports show that, in addition
to opportunistic infections, such as varicella-zoster virus, HIV infection is
known to cause endothelial dysfunction, resulting in accelerated
atherosclerosis and small vessel disease [14]. There is however a sug-
gestion that HIV sero-positivity and stroke co-occurrence may be coin-
cidental [14]. Although our study was underpowered to fully address the
influence of HIV on stroke occurrence, it is important that further studies
investigate this potential association. Results of future studies will better
inform decisionmakers and shape subsequent interventions in SSA, given
that HIV/AIDS continues to be a major public health problem in this
region.
Consistent with previous studies [5,15], our findings show that hy-
pertension (BP  140/90 mmHg) was the most important independent
risk factor for all stroke and a highly significant predictor of both stroke
subtypes. In the INTERSTROKE study [3], a history of hypertension was a
significant risk factor for all stroke. However, recent studies show that
the gradient of the relationship between hypertension and HS is steeper
than that for IS [15]. Hypertension is a well documented risk factor for
both stroke types in SSA and elsewhere, and in most cases, it is either
uncontrolled or poorly controlled [3,12]. In this study, it is a concern that
only a few of the hypertensive stroke cases were receiving antihyper-
tensive treatment. This may be a result of poor public awareness, poor
access to healthcare and perhaps poor healthcare practices, or low levels
of adherence to treatment.
In addition to hypertension, a family history of diabetes had a strong
association for both HS and IS in this study. This is consistent with earlier
studies conducted in SSA and elsewhere in the developed world [31,32].
Previous epidemiological studies have documented a three-to five-fold
increase of cardiovascular disease in diabetic individuals compared with
non-diabetic individuals [3,21,33]. Multiple indirect or direct pathways
that result in accelerated atherosclerosis have been proposed to explain
the effects of elevated glucose levels on the cardiovascular system [34,
35]. However, the relationship between the high prevalence of family
history of diabetes and cardiovascular disease could also be due to shared
genetic factors, shared environmental factors or both [31]. Given the
rising burden of non-communicable disease in SSA, the findings of the
present study, combined with existing evidence [31], indicate that un-
derstanding the genetic basis for the interactions between risk factors and
stoke can inform targeted prevention efforts, as part of a broader
approach with surveillance, prevention, acute care and rehabilitation.
Similar to previous studies from SSA, this case-control study also
showed higher numbers of IS than HS [5,15]. However, other studies in
Rwanda [36] and Ethiopia [37] have reported conflicting findings,
observing higher HS prevalence compared with IS. The distribution of
stroke types is known to differ between populations, with HSmaking up a
greater proportion of all strokes in SSA [3]. It has been reported that
higher rates of HS in SSA are related to a greater prevalence of hyper-
tension [38]. Although our study was underpowered to fully address this,
the recorded differences in prevalence rates could, in part, explain the
global variations in the incidence of IS and HS [39]. Additionally, the
variation in prevalence rates could also be due to the widely different age
compositions of the populations studied.
Most of the patients in the current study were aged 60 years, and a
female dominance was observed in both IS and HS. However, the current
study participants were much older than those in previous studies from
SSA [40], but lower than the typical age of stroke patients in the
Table 2
Risk factor association with all stroke and stroke type in Kampala, Uganda
(2016–2018).
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developed world [41]. Our results show that stroke occurs at a relatively
younger age in Uganda compared to developed countries [42], a finding
that is consistent with earlier reports in SSA [36]. Both the age and
gender distribution of our case patients differs greatly from previous
studies conducted in developed and many developing countries [37,43].
Earlier reports have shown that women tend to live longer thanmen, who
die of other comorbidities, and, as a result, women often outnumber men
in stroke prevalence figures [44]. It is equally likely that the results in the
current study reflect patterns of referral to hospital. In Tanzania, only a
small proportion of stroke patients are admitted to hospital [12].
Perhaps, men simply don’t want to go to hospital, whereas women do?
This highlights the biases associated with hospital-based studies in SSA.
4.3. Study limitations
First, as stroke patient recruitment was from a private hospital and
based on neuroimaging, our data may have a selection bias; milder
strokes cases and patients who died in the community would be
excluded. A study in East Africa used a similar approach to capture these
cases and they described similar risk factor profiles to those found in the
current study (12). Thus, the selection bias may lead to an overestimation
or and underestimation of some effects.
Second, although controls from the community would have been
ideal, hospital-based control patients were easier to recruit and generally
belonged to the same population as hospital-based case patients. Relat-
edly, the value of hospital-based controls is that the cases and controls
have the same likelihood of getting to hospital – in this regard, they are
matched. Furthermore, all cases were defined prospectively with
accepted criteria and all controls were carefully clinically screened to
eliminate individuals who may have had a subclinical disease.
Third, retrospective recall of events is often difficult and can lead to
recall bias, especially if the events were a long time ago. However, we
used some well validated tools to mitigate this. Fourth, the absence of an
association between important risk factors and HS and IS could be due to
insufficient power. Hence, larger, prospective, population-based studies
are required. Owing to the relatively small number of patients with the
ability to pay for some investigations, such as electrocardiogram (ECG),
echocardiography (ECHO) and serum lipid profiles, important risk fac-
tors, like atrial fibrillation and serum lipids, could not be investigated in
the current study. Future research is warranted to investigate the lipid
profile association with stroke in Uganda. Also, the bodyweight of many
stroke patients could not be determined with the equipment available
due to their post-stroke disability and being bed ridden. From the liter-
ature, the method used in this study of assigning weight-based de-
scriptors to individuals has a greater likelihood of patients misperceiving
their weight [45].
Finally, participant recruitment was from one urban health facility,
which has implications for generalisability of the results. While the
hospital is urban and receives patients from all parts of the country, our
study samplemay not be a true representation of the characteristics of the
urban populations in Uganda. Hence, the results may not be generalisable
to all urban settings in Uganda and thus future research should include
other urban facilities in the country.
5. Conclusions
This study found no association between HIV sero-positivity and
stroke occurrence among Ugandan stroke patients. However, hyperten-
sion and a self-reported family history of DM appeared to be significant
risk factors for both HS and IS. With the increasing burden of stroke in
SSA populations, including Uganda, interventions to reduce cardiovas-
cular risk factors should be implemented as a priority. At the individual
patient level, there should be a better effort at diagnosing and controlling
both DM and hypertension. Much larger studies may be required to
demonstrate if any association exists between HIV and stroke.
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